Vivaglobin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Common Variable Immunodeficiency

Conditions

Common Variable Immunodeficiency, Agammaglobulinemia

Trial Timeline

Mar 1, 2007 → Oct 1, 2008

NCT ID

NCT00520494

About Vivaglobin

Vivaglobin is a approved stage product being developed by CSL for Common Variable Immunodeficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00520494. Target conditions include Common Variable Immunodeficiency, Agammaglobulinemia.

What happened to similar drugs?

4 of 16 similar drugs in Common Variable Immunodeficiency were approved

Approved (4) Terminated (3) Active (10)

✅Pseudoephedrine/ParacetamolJohnson & JohnsonApproved

✅Dextromethorphan + PlaceboNovartisApproved

✅Acetylsalicylic acid (Aspirin, BAYE4465) + Paracetamol + PlaceboBayerApproved

✅Aspirin (Acetylsalicylic acid, BAYE4465) + PlaceboBayerApproved

🔄Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mgNovartisPhase 3

🔄XylometazolineNovartisPhase 3

❌Advil Congestion Relief + Advil Allergy and Congestion Relief + ParacetamolPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00701662	Phase 2	Completed	Nov 1, 2007	Jan 1, 2009	Multifocal Motor Neuropathy (MMN)
NCT00520494	Approved	Completed	Mar 1, 2007	Oct 1, 2008	Common Variable Immunodeficiency

Competing Products

20 competing products in Common Variable Immunodeficiency

See all competitors

Product	Company	Stage	Hype Score
Nasal Glucagon + Oxymetazoline	Eli Lilly	Phase 1	29
New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + Placebo	Johnson & Johnson	Phase 2	27
Pseudoephedrine/Paracetamol	Johnson & Johnson	Approved	43
Zostavax®	Merck	Pre-clinical	18
Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mg	Novartis	Phase 3	40
CDZ173	Novartis	Phase 2/3	38
Dextromethorphan + Placebo	Novartis	Approved	35
Xylometazoline	Novartis	Phase 3	40
N-acetylcysteine + Placebo	Novartis	Phase 2	35
Advil Congestion Relief + Advil Allergy and Congestion Relief + Paracetamol	Pfizer	Phase 3	32
pseudoephedrine hydrochloride 30 mg tablets + Placebo tablets	Pfizer	Phase 3	40
gammaglobulin	CSL	Pre-clinical	26
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)	CSL	Phase 3	40
Acetylsalicylic acid (Aspirin, BAYE4465) + Paracetamol + Placebo	Bayer	Approved	40
Aspirin (Acetylsalicylic acid, BAYE4465) + Placebo	Bayer	Approved	40
Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain + Acetylsalicylic Acid (Aspirin, BAYE4465) + Lidocain + Placebo	Bayer	Phase 3	37
Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine + Acetylsalicylic Acid (Aspirin, BAYE4465) + Pseudoephedrine + Placebo	Bayer	Phase 3	37
Acetylsalicylic Acid (Aspirin, BAYE4465) + Pseudoephedrine + Placebo	Bayer	Phase 3	37
Acetylcysteine + Paracetamol + Phenylephrine	Sandoz Group	Phase 3	29
A-101	Aclaris Therapeutics	Phase 3	30